2-羟基阿朴吗啡 | 64781-18-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 阿朴菲
• 中文名称: 2-羟基阿朴吗啡
• 英文名称: 2,10,11-trihydroxyaporphine
• 英文别名: 6-methyl-aporphane-2,10,11-triol；6-Methyl-aporphan-2,10,11-triol；4H-Dibenzo(de,g)quinoline-2,10,11-triol, 5,6,6a,7-tetrahydro-6-methyl-；6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,10,11-triol
• CAS: 64781-18-6
• 化学式: C₁₇H₁₇NO₃
• 分子量: 283.327
• InChiKey: QNBCPLWFVGLFHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-羟基阿朴吗啡 、 三氟乙酸酐 反应 0.17h， 生成 Trifluoro-acetic acid 6-methyl-2,10-bis-(2,2,2-trifluoro-acetoxy)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-yl ester
  参考文献：
  名称：

  Aporphines XXVI：N-甲基，N-丙基和Noraporphines的三氟乙酰基衍生物的GLC和质谱性质。

  摘要：

  制备了一系列阿菲啡碱和诺拉啡碱生物碱的O-三氟乙酰基和N，O-三氟乙酰基衍生物，并测定了它们的GLC和质谱特性。色谱分离出位置异构体apocodeine和isooapocodeine，为三氟乙酰基衍生物，其质谱图明显不同。观察到非rapophphines的N-三氟乙酰基衍生物特有的质谱裂解过程。给出了在各种化合物的质谱图中形成主要离子的合理机理。

  DOI：

  10.1002/jps.2600690819
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢溴酸 作用下， 生成 2-羟基阿朴吗啡
  参考文献：
  名称：

  Wieland; Koralek, Justus Liebigs Annalen der Chemie, 1923, vol. 433, p. 270

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES<br/>[FR] N-BENZAMIDES D'ARYLE SUBSTITUÉS ET COMPOSÉS LIÉS POUR TRAITEMENT DES MALADIES AMYLOÏDES ET DES SYNUCLÉINOPATHIES
  申请人：PROTEOTECH INC

  公开号：WO2005113489A1

  公开（公告）日：2005-12-01

  Substituted diaryl compounds of the Formulae (I, II, III), where the variables are as defined in the claims, and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aß amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

  根据权利要求中定义的变量，提供了公式（I，II，III）的取代二芳基化合物及其药学上可接受的衍生物，它们的合成，含有它们的药物组合物，以及它们在治疗淀粉样疾病中的用途，包括阿尔茨海默病中观察到的Aß淀粉样病变，如2型糖尿病中观察到的IAPP淀粉样病变，以及在帕金森病中观察到的α-突触核病变，并提供了用于制造这种治疗药物的方法。
• [EN] COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOF<br/>[FR] COMPOSITIONS ET MÉTHODES DE SUPPRESSION ET/OU DE TRAITEMENT D'UNE MALADIE LIÉE À LA CROISSANCE ET/OU DE SON ÉTAT CLINIQUE
  申请人：CK BIOTECHNOLOGY CO

  公开号：WO2020079570A1

  公开（公告）日：2020-04-23

  Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with growth or a related clinical condition thereof, are disclosed.

  本文揭示了包含一个或多个抑制CXXC5-DVL界面的药剂的治疗组合物，以及将这些治疗组合物用于模拟、治疗、减少对治疗的抵抗力、预防和诊断与生长或相关临床状况有关的疾病/疾病的方法。
• Identifying therapeutic compounds based on their physical-chemical properties
  申请人：——

  公开号：US20040105817A1

  公开（公告）日：2004-06-03

  The present invention is directed to rapid and efficient methods of identifying therapeutic compounds by allowing only the most favorable molecules initially selected based on their physical-chemical profile falling within a range predefined by the physical-chemical/biological relationship of a previously tested small subset of compounds of same core structure to be assayed; and to the therapeutic compositions identified by said methods.

  本发明旨在通过仅允许最有利的分子最初被选择，这些分子基于它们的物理化学特性落在由之前测试的具有相同核心结构的小型化合物子集的物理化学/生物学关系预定义的范围内进行测定，从而实现快速和高效的识别治疗化合物的方法；以及由该方法确定的治疗组合物。
• Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and parkinson's disease
  申请人：——

  公开号：US20040127555A1

  公开（公告）日：2004-07-01

  Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

  双和三羟基芳基化合物及其亚甲二氧基类似物和药学上可接受的酯，其合成方法，包含它们的药物组成物，以及它们在治疗淀粉样疾病中的应用，特别是Aβ淀粉样蛋白病，如阿尔茨海默病，IAPP淀粉样蛋白病，如2型糖尿病中观察到的，以及突触核蛋白病，如帕金森病中观察到的，以及用于制造此类治疗药物。
• Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
  申请人：Snow D. Alan

  公开号：US20060199838A1

  公开（公告）日：2006-09-07

  Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable derivatives, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided.

  本发明提供了取代的n-芳基苯甲酰胺，相关化合物及其药学上可接受的衍生物，它们的合成方法，含有它们的制药组合物，以及它们在治疗淀粉样疾病中的应用，包括Aβ淀粉样蛋白病，如阿尔茨海默病中观察到的IAPP淀粉样蛋白病，如2型糖尿病中观察到的以及突触核蛋白病，如帕金森病中观察到的，以及制造用于这种治疗的药物。